<DOC>
	<DOC>NCT00725608</DOC>
	<brief_summary>The purpose of this study is to evaluate the acceptability and safety of switching to Suboxone速 (buprenorphine plus naloxone) and the effect of the switch on medication dispensing. Subjects, for whom a therapy with Suboxone速 is indicated and planned prior to study enrollment and who are willing to participate, will initiate therapy on Day 1 of the study. The dosage will be adjusted between Day 2 to 7 depending on patient's needs and determined by the treating physicians in accordance with the SmPC of Suboxone速. Data will be collected at baseline, day 1 til 7, the end of weeks 2 and 4 and monthly up to the end of Month 12.</brief_summary>
	<brief_title>Acceptability and Safety of Switching From Subutex or Other Opioid Drug Dependence Therapy to Suboxone (NIS P05444)</brief_title>
	<detailed_description>Nonprobability sampling was done by invitation to volunteer.</detailed_description>
	<mesh_term>Opioid-Related Disorders</mesh_term>
	<mesh_term>Substance-Related Disorders</mesh_term>
	<mesh_term>Analgesics, Opioid</mesh_term>
	<mesh_term>Buprenorphine, Naloxone Drug Combination</mesh_term>
	<mesh_term>Buprenorphine</mesh_term>
	<mesh_term>Naloxone</mesh_term>
	<criteria>All patients on substitution therapy, that are willing to switch to Suboxone, can be included. Therapeutic indications and contraindications for Suboxone速 must be taken into consideration when selecting patients. According to product information In accordance with the product information pregnant women will be excluded.</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Suboxone</keyword>
	<keyword>Subutex</keyword>
	<keyword>Buprenorphine</keyword>
	<keyword>Naloxone</keyword>
</DOC>